The sharpest verdict: FHD-909 did not fail as a drug — it failed as a proof of concept for an entire biological hypothesis. Foghorn Therapeutics and Lilly discontinued both FHD-909 (selective SMARCA2 inhibitor) and the Selective SMARCA2 degrader program after Phase 1 data showed that selective SMARCA2 inhibition, while pharmacologically confirmed and well-tolerated, did not produce the efficacy required to advance. The press release explicitly attributes the failure to the SMARCA2/4 synthetic lethality relationship not translating clinically — meaning the foundational premise that SMARCA4-loss tumors are sufficiently dependent on SMARCA2 to be selectively killed by its inhibition was not validated in patients. This is the most dangerous failure mode in targeted oncology: on-target engagement without downstream efficacy, a pattern that cannot be rescued by medicinal chemistry optimization or dose adjustment. The simultaneous discontinuation of both an inhibitor and a degrader modality targeting the same axis removes the possibility that a different chemical approach could rehabilitate the program — the problem is upstream, at the biology. No closely comparable regulatory precedent exists: no SMARCA2 inhibitor or SMARCA2/4 synthetic lethality asset has previously reached a Phase 1 expansion decision point with disclosed outcomes, and no asset in the retrieved evidence clears the mechanistic-fit bar required to serve as a resolution precedent. The approximately 40% workforce reduction and cash runway extension into the second half of 2029 reflect survival-oriented restructuring. The pivot to EP300 and CBP degrader programs and a novel immunology and inflammation program is mechanistically distinct from the failed SMARCA2 axis, but carries no disclosed clinical validation. The sharpest remaining risk: the EP300/CBP programs are entirely preclinical, and the FHD-909 experience demonstrates that Foghorn's epigenetic platform does not guarantee clinical translation of mechanistically validated hypotheses. [1]
Phase 1 single-arm data (lowest clinical evidence tier) confirmed selective SMARCA2 inhibition and favorable safety but failed to demonstrate the efficacy required for expansion; simultaneous degrader discontinuation confirms the failure is hypothesis-driven, not compound-specific.
| Drug | FHD-909 |
| Mechanism of Action | Selective SMARCA2 inhibitor |
| Company | Foghorn Therapeutics Inc. |
| Trial Phase | Phase 1 |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Negative |
| Collaboration Partner | Lilly |
| Workforce Reduction | Approximately 40% |
| Cash Runway Extension | Into the second half of 2029 |
| Discontinued Program | Selective SMARCA2 degrader program |
| Proprietary Programs | Selective EP300 degrader, novel oral immunology and inflammation program, Selective CBP degrader |
| Platform | Induced proximity platform |
| Target Proteins | SMARCA2 (BRM), SMARCA4 (BRG1) |
| Announcement Date | October 01, 2026 |
Foghorn and Lilly Discontinue FHD-909 Development
Foghorn Therapeutics and Lilly have decided not to advance the FHD-909 program into the clinical development expansion phase, nor will they advance the Selective SMARCA2 degrader program, following a review of Phase 1 clinical data. This decision was made because the SMARCA2/4 synthetic lethality relationship did not translate into the required level of efficacy, despite FHD-909 showing selective SMARCA2 inhibition with a favorable safety profile. As a result, Foghorn is re-prioritizing its resources towards its wholly-owned proprietary pipeline, including EP300 and CBP degrader programs, and a novel immunology and inflammation program. This strategic shift, coupled with an approximately 40% workforce reduction, is expected to extend the company's cash runway into the second half of 2029.
- Program Discontinuation: Foghorn Therapeutics and Lilly have ceased further development of FHD-909 (LY4050784) and the Selective SMARCA2 degrader program. This decision follows a review of Phase 1 clinical data for FHD-909, which, despite demonstrating selective SMARCA2 inhibition and a favorable safety profile, did not achieve the necessary efficacy levels due to a lack of translation in the SMARCA2/4 synthetic lethality relationship.
- Strategic Reprioritization: Foghorn is now focusing its financial and developmental resources on its wholly-owned proprietary pipeline. Key programs include a Selective EP300 degrader, a novel oral immunology and inflammation program, and a Selective CBP degrader, all leveraging its induced proximity platform. This shift aims to advance programs with the greatest potential to address patient needs and create long-term value.
- Financial and Organizational Restructuring: To support the reprioritized pipeline, Foghorn is implementing significant organizational changes, including an approximately 40% workforce reduction. These measures are projected to extend the company's cash runway into the second half of 2029, ensuring funding for its priority programs.
SMARCA2 Setback Prompts Foghorn's Strategic Re-focus on EP300/CBP
The recent decision by Foghorn Therapeutics and Lilly to halt the FHD-909 program, a selective SMARCA2 degrader, marks a significant moment in the evolving landscape of epigenetic oncology. While the synthetic lethality concept—targeting SMARCA2 in cancers deficient in its paralog SMARCA4—holds considerable promise and has seen other SMARCA2 degraders demonstrate clinical activity, FHD-909's inability to achieve the required efficacy in Phase 1 trials underscores a critical lesson: the translation of a compelling scientific hypothesis into a successful therapeutic requires more than just target validation. It demands optimal drug design, precise target engagement, and a nuanced understanding of the biological context. This outcome highlights the inherent complexities and high-risk nature of developing novel chromatin-modifying agents, suggesting that the SMARCA2/4 synthetic lethality relationship may be more complex or drug-specific than initially understood.
Foghorn's subsequent strategic pivot towards its wholly-owned EP300 and CBP degrader programs, alongside a novel immunology and inflammation pipeline, reflects a calculated re-prioritization. The literature supports the therapeutic potential of targeting EP300 and CBP, particularly with paralog-selective degraders showing anti-cancer activity in hematological malignancies. This shift allows Foghorn to concentrate resources on assets where preclinical data and emerging insights suggest a clearer path forward, potentially leveraging lessons learned from the SMARCA2 program regarding the intricacies of epigenetic modulation. However, these new programs are not without their own development risks, as the field of selective epigenetic degrader development is still maturing, facing challenges in translating efficacy to broader patient populations. The accompanying workforce reduction, while extending the company's cash runway, also signals the challenging financial realities faced by biotech companies navigating clinical setbacks, emphasizing the critical need for focused investment and efficient resource allocation in the pursuit of innovative therapies. This strategic realignment underscores a broader industry trend: the imperative to make tough decisions to optimize resources and extend financial runways, focusing on programs with the clearest path to market and proprietary value.
Frequently Asked Questions
Contact Us
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
